Report Highlights

U.S. CRP Testing: Market Overview

The U.S. C-reactive protein testing market was valued at US$1.38 billion in 2024 and is forecast to reach US$2.05 billion by 2032, growing at a CAGR of 5.1%. Demand is structured around hospital core laboratories, national reference laboratories and physician office laboratories. Standard CRP serves inflammation monitoring, while high-sensitivity assays drive cardiovascular risk screening and account for most new reagent placements in outpatient settings. Reagent-rental and analyzer placement contracts generate most recurring revenue, so installed-base share determines competitive position.

Government has been the dominant force in shaping the market's form. The Clinical Laboratory Improvement Amendments of 1988, administered by the Centers for Medicare and Medicaid Services, set the certification tiers that determine which laboratories can run CRP testing. Private manufacturers, notably Abbott Laboratories and Roche Diagnostics, led product development in automated hs-CRP immunoturbidimetric assays, while Quest Diagnostics and Labcorp shaped volume through consolidated purchasing and national payer contracts. Government therefore sets the rules, and the private sector sets the pace.

Policy-Driven Growth in U.S. CRP Testing

Three mechanisms convert policy into CRP test volume. First, the 2018 AHA/ACC Guideline on the Management of Blood Cholesterol, issued by the American College of Cardiology and American Heart Association, classifies hs-CRP of 2.0 mg/L or higher as a risk-enhancing factor for atherosclerotic cardiovascular disease. Physicians applying this guidance order hs-CRP alongside lipid panels, translating a clinical recommendation into recurring reagent demand. Guideline recommendations are not mandates, so uptake depends on clinician adoption.

Second, Medicare Part B coverage under the Clinical Laboratory Fee Schedule pays for high-sensitivity CRP under CPT 86141 at a national rate under US$15 per test, which makes routine cardiovascular screening economically viable in hospital outpatient departments. Third, Million Hearts 2027, the HHS and CDC cardiovascular prevention initiative with a 2027 target year, sets population targets that health systems use to justify standing CRP screening protocols in primary care.

Regulatory Barriers and Compliance Costs

FDA premarket review is the first barrier. Each hs-CRP reagent and analyzer requires 510(k) clearance under Section 510(k) of the Federal Food, Drug, and Cosmetic Act, with FDA's Center for Devices and Radiological Health administering review. FY2025 standard user fees exceed US$24,000 per submission, and review timelines commonly run beyond six months when deficiency letters are issued. Manufacturers without clearance cannot sell into U.S. hospitals, which protects incumbents with cleared predicate devices.

Laboratory certification adds the second barrier. Under CLIA regulations at 42 CFR Part 493, administered by CMS, every laboratory performing CRP testing must hold a certificate matched to test complexity, and moderate-complexity hs-CRP testing requires proficiency testing enrollment and qualified personnel. Payment compression under PAMA adds the third: the Protecting Access to Medicare Act of 2014 requires private payer rate reporting that resets Medicare CLFS rates, with scheduled cuts repeatedly deferred by Congress.

Policy-Created Opportunities in U.S. CRP Testing

CLIA waiver pathways create the first opportunity. Point-of-care CRP devices receiving CLIA waiver by application under 42 CFR 493.15 can be performed in physician office laboratories without full certification, enabling same-visit cardiovascular risk stratification. Manufacturers that file waiver applications alongside 510(k) submissions can capture primary care volume that central laboratories currently process after referral.

The second opportunity lies in value-based contracting under the Medicare Shared Savings Program, established by Section 3022 of the Affordable Care Act. Accountable care organizations reporting cardiovascular quality measures have an incentive to fund standing hs-CRP screening within primary care panels, creating bundled demand. Health systems in these arrangements also favor integrated analyzer platforms that reduce turnaround time and documentation burden.

Market at a Glance

Leading Market Participants

• Abbott Laboratories
• Roche Diagnostics
• Siemens Healthineers
• Beckman Coulter
• Ortho Clinical Diagnostics
• Quest Diagnostics
• Labcorp
• Bio-Rad Laboratories
• Sysmex America
• Randox Laboratories

Regulatory and Policy Environment

The primary legislation is the Clinical Laboratory Improvement Amendments of 1988 (42 U.S.C. 263a), enforced by CMS in partnership with the FDA and the CDC. Compliance requires a CLIA certificate matched to test complexity, documented quality control, and enrollment in CMS-approved proficiency testing for regulated analytes. The Federal Food, Drug, and Cosmetic Act governs device clearance through FDA's Center for Devices and Radiological Health, while the Protecting Access to Medicare Act of 2014 (Public Law 113-93) governs Medicare CLFS rate setting.

Upcoming changes centre on PAMA rate resets, which Congress has deferred, and on laboratory-developed tests. FDA's final LDT rule, issued in May 2024, was vacated by the U.S. District Court for the Eastern District of Texas in March 2025, leaving LDT oversight under CLIA alone. Relative to regional peers, the EU In Vitro Diagnostic Regulation (EU) 2017/746 requires notified-body conformity assessment for most IVDs with transitional deadlines running through 2027 to 2029, while Canada's Medical Devices Regulations (SOR/98-282) require a medical device licence for in vitro diagnostics. The U.S. framework is faster to market but less prescriptive on pre-market evidence than the EU.

Long-Term Policy Outlook for U.S. CRP Testing

By 2032, PAMA reform is the single largest variable. Permanent rate-setting based on reported private payer data would compress Medicare CRP reimbursement, pushing smaller laboratories toward consolidation with Quest Diagnostics and Labcorp. State Medicaid programs set their own fee schedules, so price variance across states will persist alongside federal rate changes.

FDA oversight of near-patient and home testing will become the second driver as CLIA-waived digital CRP readers connect to electronic health records. HHS will define successor targets once Million Hearts 2027 concludes, determining whether standing hs-CRP screening becomes a Medicare quality expectation. Analyzers that integrate through HL7 FHIR interfaces will gain share as CMS interoperability requirements under the Interoperability and Patient Access final rule expand.